Home › NDC Lookup › Ingredients › Tretinoin › 00472-0117-20
Tretinoin .25 mg/g Cream — NDC 00472-0117-20 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NDC 00472-0117-20: Tretinoin .25 mg/g Cream

by Actavis Pharma, Inc. · 1 TUBE in 1 CARTON / 20 g in 1 TUBE

This is a package of Tretinoin .25 mg/g Cream from Actavis Pharma, Inc., first listed with the FDA Apr 1998 and currently FDA-listed, this package's marketing is listed to end Jul 2027; retail pharmacies pay about $0.5486 per g (NADAC). It is the main listing for this product, which comes in 2 package sizes.

🏷️ FDA NDC (as labeled) 0472-0117-20 billing pads the labeler segment with a zero
This package
Contains20 g in 1 tube Cost per g$0.5486 NADAC Per package$10.97 / 20 g Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.9950/unit · Part D plans $1.79/unit — full pricing hub ↓
Main listing for product 0472-0117 · Also comes in: 45 g 0472-0117-45
Rx only Brand FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 0472-0117-20 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0472 labeler · 0117 product · 20 package
Package marketed since
Apr 20, 1998
Package marketing ended
Jul 31, 2027
Sample package
No — commercial package
Barcode (UPC-A, from the NDC)
3 0472011720 9
Medicaid fills, this package
9,577 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026
⚠️
Other active recalls for Tretinoin (different manufacturers) — 3 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class III · Sep 25, 2026 — Failed Impurities/Degradation Specifications (SUN PHARMACEUTICAL INDUSTRIES INC) · FDA recall D-0034-2027
Class III · Sep 25, 2026 — Failed Impurities/Degradation Specifications (SUN PHARMACEUTICAL INDUSTRIES INC) · FDA recall D-0035-2027
Class III · Sep 25, 2026 — Failed Impurities/Degradation Specifications (SUN PHARMACEUTICAL INDUSTRIES INC) · FDA recall D-0033-2027
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0472-0117-20
Product NDC 0472-0117
11-digit billing NDC 00472011720
NCPDP billing unit GM — per gram (weight)
RxCUI 106302
UNII 5688UTC01R
Application # NDA020404
SPL Set ID b5e385a2-f6f9-41cb-8a33-eedba397043f
Established class (EPC) Retinoid
Chemical class Retinoids
DEA schedule Non-controlled
Marketing category NDA AUTHORIZED GENERIC
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 1998-04-20
Marketing end 2027-07-31
Route TOPICAL
Dosage form CREAM
Substance TRETINOIN
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90050030003703
GPI class Tretinoin
GCN Seq No 005799
GCN 22882
HICL code 002468
Ingredient (HICL) Tretinoin
HIC1 code L
Therapeutic class — broad (HIC1) Skin/Subcutaneous Tissue
HIC2 code L9
Therapeutic class — intermediate (HIC2) Dermatologic Preparations,Miscellaneous
HIC3 code L9B
Therapeutic class — specific (HIC3) Vitamin A Derivatives
AHFS code 10:00.00.00
AHFS class Antineoplastic Agents
FDB label name TRETINOIN 0.025% CREAM
FDB brand name Tretinoin
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 005799
  • GCN: 22882
  • GPI-14 (Medi-Span): 90050030003703
  • HICL (First Databank): 002468
  • AHFS class code: 10:00.00.00
  • RxCUI (RxNorm): 106302
Why two NDCs? The FDA registers this code as 0472-0117-20 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00472-0117-20. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Retinoid class.

Pharmacologic class Retinoid
Drug family (ATC) Retinoids for topical use in acne, Retinoids for cancer treatment
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name TRETINOIN 0.025% CREAM Ingredient Tretinoin
📖 What it is MedlinePlus · NLM

Tretinoin is used to treat acne. Tretinoin is also used to reduce fine wrinkles. Tretinoin is in a class of medications called retinoids. It works by increasing production of new skin cells and unclogging pores.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It depends on the form. Creams, gels and lotions treat acne, and Renova eases fine facial wrinkles. The capsules treat a blood cancer called acute promyelocytic leukemia.
  • Wash the area, pat dry, and apply a thin layer once daily, usually in the evening. Keep it away from your eyes, mouth, nose creases and mucous membranes. More does not work faster...
  • Mild warmth or stinging, redness and peeling are common. If it becomes severe, call your prescriber, who may have you use less or pause. Acne can seem to flare early on, which is n...
  • What side effects should I expect on the skin?
📖 Read our full Tretinoin guide →
1
Nutrient depletion considerations

Tretinoin may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.549 $10.97 / 20 g
Medicaid paysCMS SDUD · 12 mo $0.9950 $19.90 / 20 g
Medicare drug plans payPart D · Q2 2026 $1.79 $35.81 / 20 g
NADAC price history (per g) — tap or hover for the price & month
Dec 2024 Jul 2025 Mar 2026 Nov 2026 $1.098 $0.549
▼ Down 31% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00472-0117-20 You're viewing this Main listing 1 TUBE in 1 CARTON / 20 g in 1 TUBE $0.5486 / g $10.97 1998-04-20 Jul 31, 2027 Active
00472-0117-45 0472-0117-45 1 TUBE in 1 CARTON / 45 g in 1 TUBE $0.4806 / g $21.63 1998-04-20 Jul 31, 2027 Active

Per g, this pack runs about 14% above the cheapest pack (NDC 00472-0117-45, $0.4806 vs $0.5486 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 62% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 tube in 1 carton / 20 g in 1 tube.
What NDC number is used to bill for this package of Tretinoin .25 mg/g Cream?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Tretinoin .25 mg/g 21922-0079-06 Encube 1 tube $0.481 AB Availability likely save 12%
Tretinoin .25 mg/g 00378-8082-20 Mylan 1 tube $0.549 AB Availability likely —
Tretinoin .25 mg/gthis 00472-0117-20 Actavis 1 tube $0.549 AB Availability likely —
Tretinoin .25 mg/g 00574-2225-20 Padagis 1 tube $0.549 AB Availability likely —
Tretinoin .25 mg/g 16714-0270-01 NORTHSTAR 1 tube $0.549 AB Availability likely —
Tretinoin .25 mg/g 51672-1407-00 Sun 1 tube $0.549 AB Availability likely —
Tretinoin .25 mg/g 62332-0809-20 Alembic 1 tube $0.549 AB Availability likely —
Retin-A .25 mg/g 00187-5160-20 Bausch 1 tube $0.791 AB FDA listed +44%
Retin-A .25 mg/g 00187-5170-15 Bausch 1 tube $0.959 AB FDA listed +75%
Tretinoin .25 mg/g 00378-8086-15 Mylan 1 tube $2.465 AB Availability likely +349%
Tretinoin .25 mg/g 59651-0713-14 Aurobindo 1 tube $2.465 AB Availability likely +349%
Tretinoin .25 mg/g 00574-2325-15 Padagis 1 tube $2.465 AB Availability likely +349%
Tretinoin .25 mg/g 21922-0057-04 Encube 1 tube $2.465 AB Availability likely +349%
Tretinoin .25 mg/g 46708-0809-20 Alembic 1 tube — AB FDA listed —
Tretinoin .25 mg/g 50090-0651-00 A-S 1 tube — AB FDA listed —
Tretinoin .25 mg/g 50090-3128-00 A-S 1 tube — AB FDA listed —
Tretinoin .25 mg/g 50090-7171-00 A-S 1 tube — AB FDA listed —
Tretinoin Cream .25 mg/g 62032-0414-20 Obagi 1 tube — AB FDA listed —
Tretinoin .25 mg/g 68071-3825-02 NuCare 1 tube — AB FDA listed —
Tretinoin .25 mg/g 68071-3888-02 NuCare 1 tube — AB FDA listed —
Tretinoin .25 mg/g 68071-3945-02 NuCare 1 tube — AB FDA listed —
Tretinoin .25 mg/g 68788-4069-02 Preferred 1 tube — AB FDA listed —
Tretinoin .25 mg/g 68788-8857-02 Preferred 1 tube — AB FDA listed —
Tretinoin .25 mg/g 72162-2135-02 Bryant 1 tube — AB FDA listed —
Tretinoin .25 mg/g 71335-2898-01 Bryant 1 tube — AB FDA listed —
Tretinoin .25 mg/g 67296-2287-04 Redpharm 1 tube — AB FDA listed —
Tretinoin .25 mg/g 72578-0155-08 Viona 1 tube — AB FDA listed —
Tretinoin .25 mg/g 70771-1933-02 Zydus 1 tube — AB FDA listed —
About this product: this is an authorized generic — the brand-name product marketed without its brand name. Other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1998
Listed with the FDA since
Apr 1998
📍
2026
Currently FDA-listed
28 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Tretinoin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 1P9D0Z171K
    BHT is a synthetic antioxidant that prevents fats and oils in medicines from breaking down and becoming rancid. It helps keep the product stable and effective during storage.
  • UNII 0RE8K4LNJS
    Isopropyl myristate is an oily liquid made from coconut or palm oil. It's used in medicines as an emollient and penetration enhancer to help the medicine absorb through skin or improve spreadability in topical products.
  • UNII 13A4J4NH9I
    A synthetic emulsifier derived from stearic acid and polyethylene glycol. It helps mix oil and water-based ingredients together in liquid medicines and creams to create a smooth, uniform product.
  • UNII 1BK9DDD24E
    A synthetic polymer made from propylene glycol and a crosslinking agent. It acts as a film-former and binder in medicines, helping create coatings on tablets or holding ingredients together in solid dosage forms.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII X045WJ989B
    Sorbic acid is a preservative derived from berries that prevents mold, yeast, and bacterial growth in medicines. It keeps the product stable and safe during storage.
  • UNII 4ELV7Z65AP
    Stearic acid is a fatty acid derived from plant or animal sources. It acts as a binder and lubricant in tablets and capsules, helping them hold together and flow smoothly during manufacturing.
  • UNII 2KR89I4H1Y
    Stearyl alcohol is a waxy, fatty substance derived from natural oils or made synthetically. It acts as an emulsifier and thickener in medicines, helping mix ingredients together and give the product the right texture.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
  • UNII TTV12P4NEE
    Xanthan gum is a thickening and stabilizing ingredient made from fermented corn or other sugars. It's added to medicines to improve texture, prevent separation of liquids and solids, and help the product stay consistent.

10 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerActavis Pharma, Inc.
Application holderMYLAN PHARMACEUTICALS INC
FDA applicationNDA020404 (NDA AUTHORIZED GENERIC)
Labeler code00472
First marketedApr 1998
Product typeHuman Prescription Drug
Portfolio324 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 34 words ▾

INDICATIONS AND USAGE Tretinoin Cream, USP is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of this product in the treatment of other disorders have not been established.

⏱️ Dosage and Administration 203 words ▾

DOSAGE AND ADMINISTRATION Tretinoin Cream should be applied once a day, in the evening, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. Application may cause a transient feeling of warmth or slight stinging. In cases where it has been necessary to temporarily discontinue therapy or reduce the frequency of application, therapy may be resumed or frequency of application increased when the patients become able to tolerate the treatment.

Alterations of dose frequency should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance. Efficacy has not been established for less than once-daily dosing frequencies. During the early weeks of therapy, an apparent increase in number and exacerbation of inflammatory acne lesions may occur.

This is due, in part, to the action of the medication on deep, previously unseen lesions and should not be considered a reason to discontinue therapy. Therapeutic results should be noticed after two to three weeks but more than six weeks of therapy may be required before definite beneficial effects are seen. Patients treated with tretinoin cream may use cosmetics, but the areas to be treated should be cleansed thoroughly before the medication is applied (see PRECAUTIONS section).

⛔ Contraindications 16 words ▾

CONTRAINDICATIONS The product should not be used if there is hypersensitivity to any of the ingredients.

🤒 Adverse Reactions 116 words ▾

ADVERSE REACTIONS The skin of certain sensitive individuals may become excessively red, edematous, blistered, or crusted. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the medication dosing frequency should be adjusted temporarily to a level the patient can tolerate. However, efficacy has not been established for lower dosing frequencies.

True contact allergy to topical tretinoin is rarely encountered. Temporary hyper- or hypopigmentation has been reported with repeated application of tretinoin cream. Some individuals have been reported to have heightened susceptibility to sunlight while under treatment with tretinoin cream.

Adverse effects of tretinoin cream have been reversible upon discontinuation of therapy (see DOSAGE AND ADMINISTRATION section).

🔄 Drug Interactions 82 words ▾

Drug Interactions Concomitant topical medication, medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime should be used with caution because of possible interaction with tretinoin. Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with tretinoin cream. It also is advisable to “rest” a patient’s skin until the effects of such preparations subside before use of tretinoin cream is begun.

🤰 Pregnancy ~2 min read ▾

Pregnancy: Teratogenic Effects Oral tretinoin has been shown to be teratogenic in rats, mice, rabbits, hamsters, and subhuman primates. It was teratogenic and fetotoxic in rats when given orally in doses 1000 times the average recommended human topical clinical dose. However, variations in teratogenic doses among various strains of rats have been reported.

In the cynomolgus monkey, which metabolically is closer to humans for tretinoin than other species examined, fetal malformations were reported at oral doses of 10 mg/kg/day or greater, but none were observed at 5 mg/kg/day (1000 times the average recommended human topical clinical dose), although increased skeletal variations were observed at all doses. Dose-related increased embryolethality and abortion were reported. Similar results have also been reported in pigtail macaques.

Topical tretinoin in animal teratogenicity tests has generated equivocal results. There is evidence for teratogenicity (shortened or kinked tail) of topical tretinoin in Wistar rats at doses greater than 1 mg/kg/day (200 times the recommended human topical clinical dose). Anomalies (humerus: short 13%, bent 6%; os parietal incompletely ossified 14%) have also been reported in rats when 10 mg/kg/day was dermally applied.

Topical tretinoin (Tretinoin Cream, 0.1%) has been shown to be teratogenic in rabbits when given in doses 91 times the topical human dose for cream (assuming a 50 kg adult applies 1.0 g of 0.1% cream topically). In this study, increased incidence of cleft palate and hydrocephaly was reported in the tretinoin-treated animals. There are other reports, in New Zealand White rabbits with doses of approximately 80 times the recommended human topical clinical dose, of an increased incidence of domed head and hydrocephaly, typical of retinoid-induced fetal malformations in this species.

When given subcutaneously to rabbits, tretinoin was teratogenic at 2 mg/kg/day but not at 1 mg/kg/day. These doses are approximately 400 and 200 times, respectively, the human topical dose of tretinoin cream, 0.025% (assuming a 50 kg adult applies 1.0 g of 0.025% cream topically). In contrast, several well-controlled animal studies have shown that dermally applied tretinoin was not teratogenic at doses of 100 and 200 times the recommended human topical clinical dose, in rats and rabbits, respectively.

With widespread use of any drug, a small number of birth defect reports associated temporally with the administration of the drug would be expected by chance alone. Thirty cases of temporally associated congenital malformations have been reported during two decades of clinical use of another formulation of topical tretinoin (Retin-A). Although no definite pattern of teratogenicity and no causal association have been established from these cases, five of the reports describe the rare birth defect category, holoprosencephaly (defects associated with incomplete midline development of the forebrain).

The significance of these spontaneous reports in terms of risk to the fetus is not known. Nonteratogenic Effects Dermal tretinoin has been shown to be fetotoxic in rabbits when administered in doses 100 times the recommended topical human clinical dose. Oral tretinoin has been shown to be fetotoxic in rats when administered in doses 500 times the recommended topical human clinical dose.

There are, however, no adequate and well-controlled studies in pregnant women. Tretinoin Cream, 0.025% should not be used during pregnancy.

🆘 Overdosage 45 words ▾

OVERDOSAGE If medication is applied excessively, no more rapid or better results will be obtained and marked redness, peeling, or discomfort may occur. Oral ingestion of the drug may lead to the same side effects as those associated with excessive oral intake of vitamin A.

🧬 Clinical Pharmacology 87 words ▾

CLINICAL PHARMACOLOGY Although the exact mode of action of tretinoin is unknown, current evidence suggests that topical tretinoin decreases cohesiveness of follicular epithelial cells with decreased microcomedo formation. Additionally, tretinoin stimulates mitotic activity and increased turnover of follicular epithelial cells causing extrusion of the comedones. Pharmacokinetics: In vitro and in vivo pharmacokinetic studies with tretinoin cream indicate that less than 0.3% of the topically applied dose is bioavailable.

Circulating plasma levels of both tretinoin and isotretinoin are only slightly elevated above those found in healthy normal controls.

📦 How Supplied / Storage and Handling 51 words ▾

HOW SUPPLIED Tretinoin Cream USP, 0.025% is supplied in 20 g (NDC 0472-0117-20) and 45 g (NDC 0472-0117-45) tubes. Storage Conditions: Store below 30°C (86°F). Avoid freezing. Keep this and all medications out of the reach of children. Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054 USA Revised - November 2019

📋 Description 70 words ▾

DESCRIPTION Tretinoin Cream, USP a topical retinoid, contains tretinoin USP, 0.025% by weight in a hydrophilic cream vehicle of stearic acid, polyolprepolymer-2, isopropyl myristate, polyoxyl 40 stearate, propylene glycol, stearyl alcohol, xanthan gum, sorbic acid, butylated hydroxytoluene, and purified water. Chemically, tretinoin is all- trans- retinoic acid (C 20 H 28 0 2 ; molecular weight 300.44 vitamin A acid) and has the following structural formula: Description: C:\Documents and Settings\MBORTZ\Desktop\image.jpg

💬 Information for Patients 9 words ▾

Information for Patients See attached Patient Package Insert .

⚠️ Precautions ~3 min read ▾

PRECAUTIONS General If a reaction suggesting sensitivity or chemical irritation occurs, use of the medication should be discontinued. Exposure to sunlight, including sunlamps or artificial sunlight, should be minimized during the use of tretinoin cream, and patients with sunburn should be advised not to use the product until fully recovered because of heightened susceptibility to sunlight as a result of the use of tretinoin. Patients who may be required to have considerable sun exposure due to occupation and those with inherent sensitivity to the sun should exercise particular caution.

Use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided. Weather extremes, such as wind or cold, also may be irritating to patients under treatment with tretinoin. Tretinoin Cream, 0.025% should be kept away from the eyes, the mouth, the paranasal creases, and mucous membranes.

Topical use may induce severe local erythema and peeling at the site of application. If the degree of local irritation warrants, patients should be directed to temporarily use the medication less frequently, discontinue use temporarily, or discontinue use altogether. Efficacy at reduced frequencies of application has not been established.

Tretinoin has been reported to cause severe irritation on eczematous skin and should be used with utmost caution in patients with this condition. Information for Patients See attached Patient Package Insert . Drug Interactions Concomitant topical medication, medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime should be used with caution because of possible interaction with tretinoin.

Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with tretinoin cream. It also is advisable to “rest” a patient’s skin until the effects of such preparations subside before use of tretinoin cream is begun. Carcinogenesis, Mutagenesis and Impairment of Fertility In a life-time dermal study in CD-1 mice with another tretinoin cream, at 100 and 200 times the average recommended human topical clinical dose, a few skin tumors in the female mice and liver tumors in male mice were observed.

The biological significance of these findings is not clear because they occurred at doses that exceeded the dermal maximally tolerated dose (MTD) of tretinoin and because they were within the background natural occurrence rate for these tumors in this strain of mice. There was no evidence of carcinogenic potential when tretinoin was administered topically at a dose five times the average recommended human topical clinical dose. For purposes of comparisons of the animal exposure to human exposure, the “recommended human topical clinical dose” is defined as 1.0 g of 0.025% Tretinoin Cream applied daily to a 50 kg person.

In a chronic, two-year bioassay of vitamin A acid in mice performed by Tsubura and Yamamoto, generalized amyloid deposition was reported in all vitamin A treated groups in the basal layer of the skin. In CD-1 mice, a similar study reported hyalinization at the treated skin sites and the incidence of this finding was 0/50, 3/50, 3/50, and 2/50 in male mice and 1/50, 0/50, 4/50, and 2/50 in female mice from the vehicle control, 0.25 mg/kg, 0.5 mg/kg, and 1 mg/kg groups, respectively. Studies in hairless albino mice suggest that tretinoin may enhance the tumorigenic potential of carcinogenic doses of UVB and UVA light from a solar simulator.

In other studies, when lightly pigmented hairless mice treated with tretinoin were exposed to carcinogenic doses of UVA/UVB light, the incidence and rate of development of skin tumors were either reduced or no effect was seen. Due to significantly different experimental conditions, no strict comparison of these disparate data is possible at this time. Although the significance of these stud… [Excerpted — this section continues on DailyMed.]

🍼 Nursing Mothers 35 words ▾

Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when tretinoin cream is administered to a nursing woman.

🧬 Pharmacokinetics 42 words ▾

Pharmacokinetics: In vitro and in vivo pharmacokinetic studies with tretinoin cream indicate that less than 0.3% of the topically applied dose is bioavailable. Circulating plasma levels of both tretinoin and isotretinoin are only slightly elevated above those found in healthy normal controls.

🔬 Clinical Studies 77 words ▾

CLINICAL STUDIES In one vehicle-controlled clinical trial, Tretinoin Cream 0.025%, applied once daily was more effective than vehicle in the treatment of facial acne vulgaris of mild to moderate severity. Percent reductions in lesion count after treatment for 12 weeks in this study are shown in the following table: Tretinoin Cream, Vehicle 0.025% Cream N = Number of Subjects N = 75 N = 58 Noninflammatory Lesions 45% 27% Inflammatory Lesions 46% 32% Total Lesions 46% 28%

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ~2 min read ▾

Carcinogenesis, Mutagenesis and Impairment of Fertility In a life-time dermal study in CD-1 mice with another tretinoin cream, at 100 and 200 times the average recommended human topical clinical dose, a few skin tumors in the female mice and liver tumors in male mice were observed. The biological significance of these findings is not clear because they occurred at doses that exceeded the dermal maximally tolerated dose (MTD) of tretinoin and because they were within the background natural occurrence rate for these tumors in this strain of mice.

There was no evidence of carcinogenic potential when tretinoin was administered topically at a dose five times the average recommended human topical clinical dose. For purposes of comparisons of the animal exposure to human exposure, the “recommended human topical clinical dose” is defined as 1.0 g of 0.025% Tretinoin Cream applied daily to a 50 kg person. In a chronic, two-year bioassay of vitamin A acid in mice performed by Tsubura and Yamamoto, generalized amyloid deposition was reported in all vitamin A treated groups in the basal layer of the skin.

In CD-1 mice, a similar study reported hyalinization at the treated skin sites and the incidence of this finding was 0/50, 3/50, 3/50, and 2/50 in male mice and 1/50, 0/50, 4/50, and 2/50 in female mice from the vehicle control, 0.25 mg/kg, 0.5 mg/kg, and 1 mg/kg groups, respectively. Studies in hairless albino mice suggest that tretinoin may enhance the tumorigenic potential of carcinogenic doses of UVB and UVA light from a solar simulator. In other studies, when lightly pigmented hairless mice treated with tretinoin were exposed to carcinogenic doses of UVA/UVB light, the incidence and rate of development of skin tumors were either reduced or no effect was seen.

Due to significantly different experimental conditions, no strict comparison of these disparate data is possible at this time. Although the significance of these studies to humans is not clear, patients should minimize exposure to sun. The mutagenic potential of tretinoin was evaluated in the Ames assay and in the in vivo mouse micronucleus assay, both of which were negative.

Dermal Segment I and III studies with tretinoin cream have not been performed in any species. In oral Segment I and Segment III studies in rats with tretinoin, decreased survival of neonates and growth retardation were observed at doses in excess of 2 mg/kg/day (> 400 times the average recommended human topical clinical dose).

📄 Patient Package Insert ~3 min read ▾

PATIENT INSTRUCTIONS TRETINOIN CREAM USP, 0.025% Acne Treatment IMPORTANT Read Directions Carefully Before Using THIS LEAFLET TELLS YOU ABOUT TRETINOIN CREAM ACNE TREATMENT AS PRESCRIBED BY YOUR PHYSICIAN. THIS PRODUCT IS TO BE USED ONLY ACCORDING TO YOUR DOCTOR’S INSTRUCTIONS, AND IT SHOULD NOT BE APPLIED TO OTHER AREAS OF THE BODY OR TO OTHER GROWTHS OR LESIONS. THE SAFETY AND EFFECTIVENESS OF THIS PRODUCT IN OTHER DISORDERS HAVE NOT BEEN EVALUATED.

IF YOU HAVE ANY QUESTIONS, BE SURE TO ASK YOUR DOCTOR. PRECAUTIONS The effects of the sun on your skin: As you know, overexposure to natural sunlight or the artificial sunlight of a sunlamp can cause sunburn. Overexposure to the sun over many years may cause premature aging of the skin and even skin cancer.

The chances of these effects occurring will vary depending on skin type, the climate and the care taken to avoid overexposure to the sun. Therapy with tretinoin cream may make your skin more susceptible to sunburn and other adverse effects of the sun, so unprotected exposure to natural or artificial sunlight should be minimized. Laboratory findings: When laboratory mice are exposed to artificial sunlight, they often develop skin tumors.

These sunlight-induced tumors may appear more quickly and in greater number if the mouse is also topically treated with the active ingredient in tretinoin cream, tretinoin. In some studies, under different conditions, however, when mice treated with tretinoin were exposed to artificial sunlight, the incidence and rate of development of skin tumors were reduced. There is no evidence to date that tretinoin alone will cause the development of skin tumors in either laboratory animals or humans.

However, investigations in this area are continuing. Use caution in the sun: When outside, even on hazy days, areas treated with tretinoin cream should be protected. An effective sunscreen should be used any time you are outside (consult your physician for a recommendation of an SPF level which will provide you with the necessary high level of protection).

For extended sun exposure, protective clothing, like a hat, should be worn. Do not use artificial sunlamps or artificial sunlight while you are using Tretinoin Cream, 0.025%. If you do become sunburned, stop your therapy with tretinoin cream until your skin has recovered.

Avoid excessive exposure to wind or cold: Extremes of climate tend to dry or burn normal skin. Skin treated with tretinoin cream may be more vulnerable to these extremes. Your physician can recommend ways to manage your acne treatment under such conditions.

Possible problems: The skin of certain sensitive individuals may become excessively red, swollen, blistered, or crusted. If you are experiencing severe or persistent irritation, discontinue the use of tretinoin cream and consult your physician. There have been reports that, in some patients, areas treated with tretinoin cream developed a temporary increase or decrease in the amount of skin pigment (color) present.

Use other medication only on your physician’s advice: Only your physician knows which other medications may be helpful during treatment and will recommend them to you if necessary. Follow the physician’s instructions carefully. In addition, you should avoid preparations that may dry or irritate your skin.

These preparations may include certain astringents, toiletries containing alcohol, spices or lime, or certain medicated soaps, shampoos, and hair permanent solutions. Do not allow anyone else to use this medication. Do not use other medications with tretinoin cream which are not recommended by your doctor.

The medications you have used in the past might cause unnecessary redness or peeling. If you are pregnant, think you are pregnant, or are nursing an infant: No studies have been conducted in humans to establish the safety of tretinoin cream in pregnant women. If you are pregnant, think you are pregnant, or are nursing a baby, consult your physician before using this medica… [Excerpted — this section continues on DailyMed.]

📄 Package Label / Principal Display Panel 22 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Actavis NDC 0472-0117-20 Tretinoin Cream, USP 0.025% Rx Only For Topical Use Only 20 g (0.7 oz) image

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
9.6K
Units reimbursed last 4 qtrs
206.4K
Gross reimbursed last 4 qtrs
$205.4K
Avg / prescription
$21.44
Avg / unit
$0.9950
Latest quarter Q1 2026
355Rx
Medicaid pays / g
$0.9950
gross reimbursed
vs
NADAC / g
$0.5486
acquisition cost
=
Spread
+$0.4464
+81% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
21% FFS 79% MCO
Fee-for-service · 2,030 Rx Managed care · 7,547 Rx
State Medicaid map
Alaska: no data reported AK Maine: 540 units · 38.7 per 100k residents ME Washington: 840 units · 10.8 per 100k residents WA Idaho: 285 units · 14.5 per 100k residents ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: 22,425 units · 223 per 100k residents MI New York: 18,095 units · 92.5 per 100k residents NY Vermont: no data reported VT New Hampshire: 800 units · 57.1 per 100k residents NH Oregon: no data reported OR Nevada: 1,560 units · 48.8 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 700 units · 21.8 per 100k residents IA Illinois: 4,460 units · 35.5 per 100k residents IL Indiana: no data reported IN Ohio: 15,665 units · 133 per 100k residents OH Pennsylvania: 1,920 units · 14.8 per 100k residents PA New Jersey: 6,420 units · 69.1 per 100k residents NJ Massachusetts: 2,520 units · 36.0 per 100k residents MA California: 22,880 units · 58.7 per 100k residents CA Utah: 340 units · 10.0 per 100k residents UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: 12,940 units · 148 per 100k residents VA Maryland: 23,280 units · 377 per 100k residents MD Connecticut: 300 units · 8.3 per 100k residents CT Rhode Island: 12,400 units · 1,132 per 100k residents RI Arizona: no data reported AZ New Mexico: 480 units · 22.7 per 100k residents NM Kansas: 1,100 units · 37.4 per 100k residents KS Arkansas: no data reported AR Tennessee: 3,065 units · 43.0 per 100k residents TN North Carolina: 880 units · 8.1 per 100k residents NC South Carolina: 320 units · 6.0 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: 1,365 units · 29.8 per 100k residents LA Mississippi: 1,840 units · 62.6 per 100k residents MS Alabama: no data reported AL Georgia: 34,655 units · 314 per 100k residents GA D.C.: 1,285 units · 189 per 100k residents DC Hawaii: 280 units · 19.5 per 100k residents HI Texas: 12,750 units · 41.8 per 100k residents TX Florida: no data reported FL
Units reimbursed · per 100k residents
6.01,132
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Rhode Island 1,132 /100k
2 Maryland 377 /100k
3 Georgia 314 /100k
4 Michigan 223 /100k
5 D.C. 189 /100k
6 Virginia 148 /100k
7 Ohio 133 /100k
8 New York 92.5 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube this page00472-0117-20 9,577 Rx · $205,367
1 tube00472-0117-45 5,898 Rx · $301,336
Drug total (last 4 qtrs): 15,475 Rx · 473,696 units · $506,703 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Tretinoin — the program that covers self-administered drugs. 12 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Tretinoin. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$5.59M
Claims incl. refills
77.6K
Beneficiaries
59.9K
Spend / beneficiary
$93.38
Spend / claim
$72.01
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for TRETINOIN — the ingredient across all brands.

Top reported reactions

Pain597
Vomiting499
Rash476
Nausea452
Headache434
Diarrhoea414
Paraesthesia408

Age at onset

Neonate9
Infant3
Child36
Adolescent109
Adult991
Elderly209

Reporter sex

8,742 reports
Male · 22%
Female · 77%
Unknown · 1%

Serious outcomes

Hospitalization1,705
Death867
Life-threatening498
Disabling356
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 917 430
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.